Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
Key facts
- Who runs it
- Albert Einstein Healthcare Network
- Where
- Ann Arbor, Birmingham, Boston, Brooklyn, Chapel Hill, Charleston, Durham, Fresno, Gainesville, Houston, Indianapolis, Kansas City, Loma Linda, Miami, Philadelphia, Phoenix, The Bronx, and West Haven, United StatesSee the 19 sites
- Trial code
- Status
- Completed
- People taking part
- 1,494 people enrolled
- Started
- 30 Jan 2019
- Ended
- 30 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Palliative Care
- Record updated
- 2 December 2025
Who can take part
- Age
- 18 years to 120 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Eligible patients were adults (≥18 years) with:
- cirrhosis and a decompensation event indicative of ESLD (such as ascites, variceal bleeding or hepatic encephalopathy) within the prior 6 months, or
- hepatocellular cancer (HCC) except Barcelona Stage D, or multifocal HCC (as defined by standard guidelines and confirmed by treating hepatologist); Additional inclusion criteria included English literacy and the capacity to complete study assessments
Where in United States
- University of Michigan Medical CenterAnn Arbor, United States
- University of AlabamaBirmingham, United States
- VA BostonBoston, United States
- VA New York HarborBrooklyn, United States
- UNC Liver CenterChapel Hill, United States
- Medical University of South CarolinaCharleston, United States
- Durham V.A. Medical CenterDurham, United States
- Ucsf FresnoFresno, United States
- University of FloridaGainesville, United States
- Baylor College of MedicineHouston, United States
- Indiana UniversityIndianapolis, United States
- Kansas City VA Medical CenterKansas City, United States
- Loma Linda Unversity HealthLoma Linda, United States
- Miami VA Medical CenterMiami, United States
- Albert Einstein Medical CenterPhiladelphia, United States
- Corporal Michael J. Crescenz VA Medical CenterPhiladelphia, United States
- Banner Health- University Medical CenterPhoenix, United States
- VA BronxThe Bronx, United States
- VA West HavenWest Haven, United States
About the trial
What the trial wants to find out
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are:
Read full original descriptionShow less
Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services)
Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-Hep (Functional Assessment of Cancer Therapy- Hepatobiliary).
Primary Hypothesis: Compared to consultative PC, the trained hepatologist-led PC for ESLD patients will show superior primary outcome. In the event of nonsignificant superiority, the trained hepatologist-led PC led will show non-inferiority (NI) by ruling out a 4-point reduction (NI margin) in mean of the primary outcome as compared to the consultative PC.
Power: The study has 83.2% power to detect minimal clinically important difference (MCID) of 9 points in mean of the primary outcome between the two randomized arms. We have 79.2% power for the noninferiority hypothesis, under assumption that the trained hepatologist-led PC arm performs better than the consultative PC arm by half of the above MCID.
Setting: 19 Clinical Centers across US are recruited to participate in this study.
Qualitative nested study will interview patients, caregivers and providers to assess their experiences with participating in the palliative care trial.
The 2 groups in the trial
- Model 1: Consultative Palliative CareExisting treatment, for comparison
Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
Treatment: Palliative Care
- Model 2: Trained Hepatologist- led PCExisting treatment, for comparison
A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
Treatment: Palliative Care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD): A Cluster Randomized Controlled Trial
- Publications
- Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial.JAMA internal medicine, 2026
- Record updated
- 2 December 2025